Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vopimetostat - Tango Therapeutics

Next Previous
Drug Profile

Vopimetostat - Tango Therapeutics

Alternative Names: TNG-462

Latest Information Update: 13 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tango Therapeutics
  • Class Alkanes; Amides; Aminopyridines; Antineoplastics; Benzothiazoles; Ketones; Piperidines; Small molecules
  • Mechanism of Action PRMT5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Soft tissue sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Adenocarcinoma; Non-small cell lung cancer; Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 05 Mar 2026 Erasca and Tango Therapeutics enters into clinical trial collaboration and supply agreement to evaluate ERAS-0015 and vopimetostat (TNG462) for Pancreatic cancer and Non small cell lung cancer
  • 05 Mar 2026 Erasca in collaboration with Tango Therapeutics plans phase I/II trial in Pancreatic and Non small cell lung cancer (Combination therapy)
  • 05 Nov 2025 Chemical structure information added.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top